Education
About Us
Working with TipRanks
Follow Us
Gentian Diagnostics ASA (DE:6FK)
:6FK
6FK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.00 - €5.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€62.73M
Enterprise Value€617.30M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)5.39M
Price to Earnings (P/E)16.5
Beta0.57
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding15,422,350
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.51
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Gentian Diagnostics ASA News
PremiumCompany Announcements
Gentian Diagnostics Insider Share Sale Notification
PremiumCompany Announcements
Gentian Diagnostics Sees Significant Share Acquisition by INSR and Norda
PremiumCompany Announcements
Gentian Diagnostics Reports Record Sales and Strong Growth in Q4 2024
PremiumCompany Announcements
Gentian Diagnostics Reports Strong Revenue Growth and Strategic Advances
PremiumCompany Announcements
Gentian Diagnostics Mourns Founder’s Passing
PremiumCompany Announcements
Gentian Diagnostics Secures Patent for Diagnostic Precision
PremiumCompany Announcements
Gentian Diagnostics Posts Strong Q2 Growth
PremiumCompany Announcements
Gentian Diagnostics Welcomes New CTO Frank Frantzen---
6FK FAQ
What was Gentian Diagnostics ASA’s price range in the past 12 months?
Gentian Diagnostics ASA lowest stock price was €3.00 and its highest was €5.05 in the past 12 months.
What is Gentian Diagnostics ASA’s market cap?
Gentian Diagnostics ASA’s market cap is €62.73M.
When is Gentian Diagnostics ASA’s upcoming earnings report date?
Gentian Diagnostics ASA’s upcoming earnings report date is May 07, 2025 which is in 58 days.
How were Gentian Diagnostics ASA’s earnings last quarter?
Gentian Diagnostics ASA released its earnings results on Feb 12, 2025. The company reported €0.181 earnings per share for the quarter, beating the consensus estimate of N/A by €0.181.
Is Gentian Diagnostics ASA overvalued?
According to Wall Street analysts Gentian Diagnostics ASA’s price is currently Overvalued.
Does Gentian Diagnostics ASA pay dividends?
Gentian Diagnostics ASA does not currently pay dividends.
What is Gentian Diagnostics ASA’s EPS estimate?
Gentian Diagnostics ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gentian Diagnostics ASA have?
Gentian Diagnostics ASA has 15,422,350 shares outstanding.
What happened to Gentian Diagnostics ASA’s price movement after its last earnings report?
Gentian Diagnostics ASA reported an EPS of €0.181 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.471%.
Which hedge fund is a major shareholder of Gentian Diagnostics ASA?
Currently, no hedge funds are holding shares in DE:6FK
---
Company Description
Gentian Diagnostics ASA
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic tests (IVD tests) for the use in medical diagnostics and research. It offers test solutions in the areas of kidney disease, cardiovascular diseases, inflammation, veterinary, and oncology. It offers products including in vitro diagnostic products for the detection and quantification.
---
Technical Analysis
---